Lagatar24 Desk
Hyderabad, Nov.12: A new study published in The Lancet has stated that Bharat Biotech’s indigenous Covid-19 vaccine is highly efficacious, well tolerated, and poses no safety concerns. Covaxin was reported to have a 77.8% effectiveness rate against symptomatic Covid-19 patients, according to the medical publication.
Two weeks after two doses of Covaxin, which uses classic, inactivated-virus technology, “induces a substantial antibody response.” During a randomised experiment comprising 24,419 people aged 18 to 97 years in India between November 2020 and May 2021, no serious vaccine-related deaths or adverse events were observed, according to the study.
Covaxin was tested against all ciruclating variations during the second wave of Covid-19 infections in India, with a high of more than 400 000 new cases each day, according to the study.
“Our prior observations on the safety and immunogenicity profiles of BBV152 in phase 1 and 2 studies were confirmed by this investigation.” No safety concerns were raised, no anaphylactic episodes were recorded following BBV152 delivery, and all adverse events (solicited, unsolicited, and major adverse events) were evenly distributed between the BBV152 and placebo groups, according to the paper.
Only one significant adverse event was reported in the vaccine group during the study: a case of immune thrombocytopenic purpura 39 days after the second dose in a vaccine recipient who was SARS-CoV-2 seropositive at the start. The incident, however, was remedied in four days, according to the report. “All other major side effects were determined to be unrelated to the vaccine or placebo.” The Lancet said that “long-term safety monitoring is ongoing and will continue for one year after administration of the first dosage of BBV152.”
The Lancet release comes a week after Covaxin was approved for emergency use by the World Health Organization (WHO), easing the lives of lakhs of Indians whose overseas travel plans were hampered by the shot’s non-recognition.
Since the beginning of the immunisation programme in January, more than 12 crore doses of Covaxin have been provided.
During the experiment, there were no severe vaccine-related adverse events, and the majority of the adverse events were mild, including headache, weariness, and injection site soreness.
